Prevention and treatment of tuberculosis infection in candidates for biologic therapy: A multidisciplinary consensus statement adapted to the dermatology patient

Rodríguez‐Jiménez, Pedro; Mir-Viladrich, Isabel; Chicharro, Pablo; Solano-López, G.; Lόpez-Longo, FJ; Taxonera, Carlos; Sánchez‐Martínez, Francesca; Martínez-Lacasa, Xavier; García-Gasalla, Mercedes; Dorca, Jordi; Arias-Guillén, Miguel; García-García, José-María; Daudén, E.

doi:10.1016/j.adengl.2018.06.020

Cited by 2 publications

(3 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In fact, a higher TB risk is associated with monoclonal anti-TNF agents compared with soluble receptor etanercept. [24][25][26] Nevertheless, adalimumab was the second most administered drug; the other TNFi (golimumab, infliximab and certolizumab) were commonly employed as well, without showing any significant differences compared with the non-TNFi (abatacept, tocilizumab and rituximab). This might imply that despite the increased risk of TB reactivation associated with TNFi use, intrinsic to the mechanism of action related to granuloma formation and stability, effective screening and preventive therapy protocols had ensured a control of Mtb containment during bDMARDs administration.…”

Section: Discussionmentioning

confidence: 99%

“…This choice is consistent with the safety profile of this drug compared with other TNFi. In fact, a higher TB risk is associated with monoclonal anti‐TNF agents compared with soluble receptor etanercept 24–26 . Nevertheless, adalimumab was the second most administered drug; the other TNFi (golimumab, infliximab and certolizumab) were commonly employed as well, without showing any significant differences compared with the non‐TNFi (abatacept, tocilizumab and rituximab).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence and management of tuberculosis infection in Apulian rheumatologic patients treated with biologics: An observational cohort 10‐year study from the BIOPURE registry

Fornaro

Stano

Goletti

et al. 2022

Eur J Clin Investigation

View full text Add to dashboard Cite

Introduction:The objective of this study was to assess the 10-year prevalence of latent tuberculosis infection (LTBI) among Apulian patients with rheumatic diseases (RDs). Secondary endpoint was to record new cases of active TB disease and LTBI among patients treated with biologic disease-modifying antirheumatic drugs (bDMARDs). Methods: We analysed the results from the patients included in the BIOPURE registry from 2009 to 2018, who underwent QuantiFERON-TB Gold In-tube (QFT-GIT) test as screening before bDMARDs treatment. Demographic and clinical data were recorded at the time of the first QFT-GIT test. Administration of preventive therapy and bDMARD treatments were recorded for patients with positive QFT-GIT test. All new tuberculosis infections were recorded during the follow-up. Results:The final study population included 3028 patients (855 rheumatoid arthritis, 1001 psoriatic arthritis, 833 spondyloarthritis, 130 connective tissue diseases, 33 systemic vasculitis and 176 other inflammatory rheumatic conditions), more frequently female (67.2%), with a mean age of 52 ± 18 years. Patients with QFT-GIT-positive test were elderly people, predominantly male with higher prevalence of diabetes as comorbidity. The 10-year prevalence of LTBI was 10.8%. Of note, no cases of TB reactivation were recorded in patients who completed preventive therapy treatment. Three thousand and sixteen patients were followed over time (42.6 ± 30 months), and five (.2%) developed active TB, which corresponds to .47 cases per 1000 person-years. Conclusions:In the 10-year observation, the use of bDMARDs seems to be safe in rheumatologic patients with positive QFT-GIT test treated according to current

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Prevalence and management of tuberculosis infection in Apulian rheumatologic patients treated with biologics: An observational cohort 10‐year study from the BIOPURE registry

Fornaro

Stano

Goletti

et al. 2022

Eur J Clin Investigation

View full text Add to dashboard Cite

show abstract

“…D.pacientes de segunda linha do registro PSOLAR. A linha vermelha vertical pontilhada indica o mesmo intervalo de tempo entre as quatro curvas O risco de desenvolver tuberculose é maior em pacientes recebendo as drogas anti-TNF-α INF e ADA do que aqueles recebendo ETA (Tubach et al, 2009;Ergun et al, 2015;Rodríguez-Jiménez et al, 2018). O TNF-α tem papel primordial na manutenção do granuloma da tuberculose e, com seu bloqueio pelos seus antagonistas, as formas disseminadas e extrapulmonares ocorrem com mais frequência (Dobler, 2016).…”

Section: Análise De Sobrevida Da Drogaunclassified

Resposta terapêutica e tempo de sobrevida dos imunobiológicos em pacientes com psoríase moderada a grave

Mota¹

View full text Add to dashboard Cite

Prevention and treatment of tuberculosis infection in candidates for biologic therapy: A multidisciplinary consensus statement adapted to the dermatology patient

Cited by 2 publications

References 85 publications

Prevalence and management of tuberculosis infection in Apulian rheumatologic patients treated with biologics: An observational cohort 10‐year study from the BIOPURE registry

Prevalence and management of tuberculosis infection in Apulian rheumatologic patients treated with biologics: An observational cohort 10‐year study from the BIOPURE registry

Resposta terapêutica e tempo de sobrevida dos imunobiológicos em pacientes com psoríase moderada a grave

Contact Info

Product

Resources

About